Multivariate optimization and validation of an analytical methodology by RP-HPLC for the determination of losartan potassium in capsules

dc.creatorBonfilio, R
dc.creatorTarley, CRT
dc.creatorPereira, GR
dc.creatorSalgado, HRN
dc.creatorde Araujo, MB
dc.date2009
dc.date42309
dc.date2014-11-14T23:01:02Z
dc.date2015-11-26T16:08:49Z
dc.date2014-11-14T23:01:02Z
dc.date2015-11-26T16:08:49Z
dc.date.accessioned2018-03-28T22:57:23Z
dc.date.available2018-03-28T22:57:23Z
dc.identifierTalanta. Elsevier Science Bv, v. 80, n. 1, n. 236, n. 241, 2009.
dc.identifier0039-9140
dc.identifierWOS:000271055700036
dc.identifier10.1016/j.talanta.2009.06.060
dc.identifierhttp://www.repositorio.unicamp.br/jspui/handle/REPOSIP/82059
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/82059
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/82059
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1266457
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionThis paper describes the optimization and validation of an analytical methodology for the determination of losartan potassium in capsules by HPLC using 2(5-1) fractional factorial and Doehlert designs. This multivariate approach allows a considerable improvement in chromatographic performance using fewer experiments, without additional cost for columns or other equipment. The HPLC method utilized potassium phosphate buffer (pH 6.2: 58 mmol L(-1))-acetonitrile (65:35, v/v) as the mobile phase, pumped at a flow rate of 1.0 mL min(-1). An octylsilane column (100 mm x 4.6 mm W., 5 mu m) maintained at 35 degrees C was used as the stationary phase. UV detection was performed at 254 nm. The method was validated according to the ICH guidelines, showing accuracy, precision (intra-day relative standard deviation (R.S.D.) and inter-day R.S.D values <2.0%). selectivity, robustness and linearity (r=0.9998) over a concentration range from 30 to 70 mg L(-1) of losartan potassium. The limits of detection and quantification were 0.114 and 0.420 mg L(-1), respectively. The validated method may be used to quantify losartan potassium in capsules and to determine the stability of this drug. (C) 2009 Elsevier B.V. All rights reserved.
dc.description80
dc.description1
dc.description236
dc.description241
dc.descriptionCenter of Pharmaceutical Equivalence of the Federal University of Alfenas
dc.descriptionFederal University of Alfenas
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.descriptionConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
dc.languageen
dc.publisherElsevier Science Bv
dc.publisherAmsterdam
dc.publisherHolanda
dc.relationTalanta
dc.relationTalanta
dc.rightsfechado
dc.rightshttp://www.elsevier.com/about/open-access/open-access-policies/article-posting-policy
dc.sourceWeb of Science
dc.subjectDoehlert design
dc.subjectFractional factorial design
dc.subjectLosartan potassium
dc.subjectReversed-phase chromatography
dc.subjectValidation
dc.subjectPerformance Liquid-chromatography
dc.subjectThin-layer-chromatography
dc.subjectMass-spectrometry
dc.subjectCozaar(r) Tablets
dc.subjectHuman Plasma
dc.subjectDosage Form
dc.subjectHydrochlorothiazide
dc.subjectPhase
dc.subjectBioequivalence
dc.subjectDegradation
dc.titleMultivariate optimization and validation of an analytical methodology by RP-HPLC for the determination of losartan potassium in capsules
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución